Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: True associations or bias?

European Journal of Epidemiology

Volumn 27, Issue 6, 2012, Pages 439-452

  Morois, Sophie ^a,b   Fournier, Agnès ^a,b   Clavel Chapelon, Françoise ^a,b   Mesrine, Sylvie ^a,b   Boutron Ruault, Marie Christine ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Adenoma; Cohort studies; Colorectal neoplasms; Menopausal hormone therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; WOMEN'S HEALTH;

ADENOMA; ADULT; AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION ROUTES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRANCE; HUMANS; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84863719107     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-012-9694-6     Document Type: Article

References (56)

1. Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique. 2008;56(3):159-75.
2. Murphy G, Devesa SS, Cross AJ, et al. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer. 2011;128(7):1668-75.
3. Nanda K, Bastian LA, Hasselblad V, et al. Hormone replacement therapy and the risk of colorectal cancer: A meta-analysis. Obstet Gynecol. 1999;93(5 Pt 2):880-8.
4. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med. 1999;106(5):574-82.
5. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev. 1998;7(8):653-9.
6. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004.
7. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58-66.
8. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-45.
9. Ritenbaugh C, Stanford JL, Wu L, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: The Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2609-18.
10. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA. 2011;305(13):1305-14.
11. Prentice RL, Pettinger M, Beresford SA, et al. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev. 2009;18(5): 1531-7.
12. Hildebrand JS, Jacobs EJ, Campbell PT, et al. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2835-41.
13. Tsilidis KK, Allen NE, Key TJ, et al. Menopausal hormone therapy and risk of colorectal cancer in the European prospective investigation into cancer and nutrition. Int J Cancer. 2011;128(8): 1881-9.
14. Delellis HK, Duan L, Sullivan-Halley J, et al. Menopausal hormone therapy use and risk of invasive colon cancer: The California teachers study. Am J Epidemiol. 2010;171(4):415-25.
15. Johnson JR, Lacey JV Jr, Lazovich D, et al. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(1):196-203.
16. Lin KJ, Cheung WY, Lai JY, et al. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer. 2012;130(2):419-30.
17. Green J, Czanner G, Reeves G, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: Nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer. 2012;130(10):2387-96.
18. Csizmadi I, Collet JP, Benedetti A, et al. The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. Br J Cancer. 2004;90(1): 76-81.
19. Dinger JC, Heinemann LA, Mohner S, et al. Colon cancer risk and different HRT formulations: A case-control study. BMC Cancer. 2007;776.
20. Corrao G, Zambon A, Conti V, et al. Menopause hormone replacement therapy and cancer risk: An Italian record linkage investigation. Ann Oncol. 2008;19(1):150-5.
21. Rennert G, Rennert HS, Pinchev M, et al. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol. 2009;27(27):4542-7.
22. Hoffmeister M, Raum E, Krtschil A, et al. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Ther. 2009;86(4):416-24.
23. Kabat GC, Miller AB, Rohan TE. Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women. Int J Cancer. 2008;122(3):643-6.
24. Hoffmeister M, Raum E, Winter J, et al. Hormone replacement therapy, body mass, and the risk of colorectal cancer among postmenopausal women from Germany. Br J Cancer. 2007; 97(11):1486-92.
25. Prihartono N, Palmer JR, Louik C, et al. A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(4):443-7.
26. Jacobson JS, Neugut AI, Garbowski GC, et al. Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). Cancer Causes Control. 1995;6(6):513-8.
27. Terry MB, Neugut AI, Bostick RM, et al. Risk factors for advanced colorectal adenomas: A pooled analysis. Cancer Epidemiol Biomarkers Prev. 2002;11(7):622-9.
28. Woodson K, Lanza E, Tangrea JA, et al. Hormone replacement therapy and colorectal adenoma recurrence among women in the polyp prevention trial. J Natl Cancer Inst. 2001;93(23):1799-805.
29. Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998;128(9):705-12.
30. Murff HJ, Shrubsole MJ, Smalley WE, et al. The interaction of age and hormone replacement therapy on colon adenoma risk. Cancer Detect Prev. 2007;31(2):161-5.
31. Purdue MP, Mink PJ, Hartge P, et al. Hormone replacement therapy, reproductive history, and colorectal adenomas: Data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes Control. 2005;16(8):965-73.
32. Gondal G, Grotmol T, Hofstad B, et al. Lifestyle-related risk factors and chemoprevention for colorectal neoplasia: Experience from the large-scale NORCCAP screening trial. Eur J Cancer Prev. 2005;14(4):373-9.
33. Morimoto LM, Newcomb PA, Ulrich CM, et al. Risk factors for hyperplastic and adenomatous polyps: Evidence for malignant potential? Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1012-8.
34. Chen MJ, Longnecker MP, Morgenstern H, et al. Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1998;7(3): 227-30.
35. Peipins LA, Newman B, Sandler RS. Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1997;6(9):671-5.
36. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: The Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev. 1996;5(10):779-84.
37. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-11.
38. Clavel-Chapelon F, van Liere MJ, Giubout C, et al. E3N, a French cohort study on cancer risk factors. E3N Group. Etude Epidemiologique aupres de femmes de l'Education Nationale. Eur J Cancer Prev. 1997;6(5):473-8.
39. Tehard B, van Liere MJ, Com Nougue C, et al. Anthropometric measurements and body silhouette of women: Validity and perception. J Am Diet Assoc. 2002;102(12):1779-84.
40. van Liere MJ, Lucas F, Clavel F, et al. Relative validity and reproducibility of a French dietary history questionnaire. Int J Epidemiol. 1997;26(Suppl 1):S128-36.
41. Morois S, Mesrine S, Josset M, et al. Anthropometric factors in adulthood and risk of colorectal adenomas: The French E3N-EPIC prospective cohort. Am J Epidemiol. 2010;172(10):1166-80.
42. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut. 2002;51(1):130-1.
43. Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980;67(1):145-53.
44. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: Competing risks and multi-state models. Stat Med. 2007;26(11): 2389-430.
45. Long MD, Martin CF, Galanko JA, et al. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: A population-based case-control study. Am J Gastroenterol. 2010;105(8):1843-50.
46. Campbell PT, Newcomb P, Gallinger S, et al. Exogenous hormones and colorectal cancer risk in Canada: Associations stratified by clinically defined familial risk of cancer. Cancer Causes Control. 2007;18(7):723-33.
47. Newcomb PA, Zheng Y, Chia VM, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 2007;67(15):7534-9.
48. Clendenen TV, Koenig KL, Shore RE, et al. Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(1):275-81.
49. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008;68(1):329-37.
50. Zervoudakis A, Strickler HD, Park Y, et al. Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst. 2011;103(10):826-34.
51. Di Domenico M, Castoria G, Bilancio A, et al. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res. 1996;56(19):4516-21.
52. Javid SH, Moran AE, Carothers AM, et al. Modulation of tumour formation and intestinal cell migration by estrogens in the Apc(Min/?) mouse model of colorectal cancer. Carcinogenesis. 2005;26(3):587-95.
53. Giroux V, Lemay F, Bernatchez G, et al. Estrogen receptor beta deficiency enhances small intestinal tumourigenesis in ApcMin/ ?mice. Int J Cancer. 2008;123(2):303-11.
54. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256-66.
55. Robins JM. Data, design, and background knowledge in etiologic inference. Epidemiology. 2001;12(3):313-20.
56. Sandini L, Pentti K, Tuppurainen M, et al. Agreement of selfreported estrogen use with prescription data: An analysis of women from the Kuopio Osteoporosis risk factor and prevention study. Menopause. 2008;15(2):282-9.